BIAS
VRTX icon

Beacon Investment Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Beacon Investment Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5M Sell
53,380
-2,724
-5% -$1.21M 0.98% 31
2026
Q1 		$25.1M Sell
56,104
-17,989
-24% -$8.39M 1.03% 29
2025
Q4 		$33.6M Sell
74,093
-2,049
-3% -$883K 1.37% 18
2025
Q3 		$29.8M Sell
76,142
-889
-1% -$372K 1.25% 21
2025
Q2 		$34.3M Sell
77,031
-870
-1% -$401K 1.51% 18
2025
Q1 		$37.8M Sell
77,901
-923
-1% -$430K 1.77% 11
2024
Q4 		$31.7M Sell
78,824
-347
-0.4% -$161K 1.38% 21
2024
Q3 		$36.8M Sell
79,171
-61
-0.1% -$29.3K 1.53% 20
2024
Q2 		$37.1M Buy
79,232
+1,515
+2% +$658K 1.59% 20
2024
Q1 		$32.5M Sell
77,717
-203
-0.3% -$85.8K 1.4% 21
2023
Q4 		$31.7M Buy
77,920
+1,679
+2% +$620K 1.44% 22
2023
Q3 		$26.5M Buy
76,241
+1,968
+3% +$688K 1.31% 24
2023
Q2 		$26.1M Buy
74,273
+265
+0.4% +$89.3K 1.2% 25
2023
Q1 		$23.3M Sell
74,008
-832
-1% -$250K 1.13% 27
2022
Q4 		$21.6M Buy
74,840
+423
+0.6% +$129K 1.11% 26
2022
Q3 		$21.5M Sell
74,417
-455
-0.6% -$131K 1.19% 26
2022
Q2 		$21.1M Buy
74,872
+1,779
+2% +$476K 1.1% 27
2022
Q1 		$19.1M Buy
73,093
+42,536
+139% +$10.1M 0.81% 36
2021
Q4 		$6.71M Sell
30,557
-5,945
-16% -$1.16M 0.26% 80
2021
Q3 		$6.62M Sell
36,502
-398
-1% -$77.7K 0.27% 83
2021
Q2 		$7.44M Sell
36,900
-745
-2% -$156K 0.3% 76
2021
Q1 		$8.09M Buy
37,645
+202
+0.5% +$44.4K 0.35% 69
2020
Q4 		$8.85M Sell
37,443
-1,709
-4% -$392K 0.41% 64
2020
Q3 		$10.7M Buy
39,152
+709
+2% +$196K 0.55% 54
2020
Q2 		$11.2M Buy
38,443
+13,060
+51% +$3.54M 0.64% 48
2020
Q1 		$6.04M Buy
+25,383
New +$5.82M 0.43% 63

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Beacon Investment Advisory Services's VRTX Position: Q2 2026 in Review

Beacon Investment Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 4.9% in Q2 2026, selling an estimated $1.21M and leaving 53,380 shares worth $26.5M. The position accounts for 0.98% of the portfolio, ranked #31.

Beacon Investment Advisory Services first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $37.8M in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Beacon Investment Advisory Services held 53,380 shares of Vertex Pharmaceuticals worth $26.5M as of Q2 2026.
  • Beacon Investment Advisory Services sold 2,724 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.21M.
  • Vertex Pharmaceuticals made up 0.98% of Beacon Investment Advisory Services's portfolio in Q2 2026, its #31 holding.
  • Beacon Investment Advisory Services first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Beacon Investment Advisory Services's Vertex Pharmaceuticals position peaked at $37.8M in Q1 2025.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Beacon Investment Advisory Services's 13F filing for Q2 2026, filed 8 Jul 2026.